Learning Center

Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death.

These data, together with the previously reported beneficial effect in colitis, suggest that TUDCA could be an add-on strategy to current immunosuppressive treatment of ulcerative colitis patients.